<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00640250</url>
  </required_header>
  <id_info>
    <org_study_id>Mekos 07 2P3.2 201</org_study_id>
    <secondary_id>2007-007130-19</secondary_id>
    <secondary_id>WIRB Pr. No.: 20072233</secondary_id>
    <nct_id>NCT00640250</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of T.R.U.E. TEST速 Panel 3.2 Allergens: Dose Response</brief_title>
  <official_title>Clinical Evaluation of T.R.U.E. TEST速 Panel 3.2 Allergens: Bronopol and Disperse Blue 106 Dose Response Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allerderm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allerderm</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We propose a prospective, multi-center, double-blind, randomized study comparing the
      diagnostic performance (primary) and safety (secondary) of 3 concentrations of Disperse blue
      106 and 4 concentrations of Bronopol in 40 adult subjects (20 subjects per allergen) with a
      clinical history of contact dermatitis and a positive patch test (current or previous) to the
      corresponding reference petrolatum allergen (&quot;sensitives&quot;).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary endpoint:

      To evaluate the diagnostic performance of Disperse blue 106 and Bronopol T.R.U.E. Test
      allergens in 20 adult subjects per allergen with a clinical history of contact dermatitis and
      a positive patch test to the respective reference allergen. Evaluations will include:

        -  Determination of the lowest concentration eliciting positive skin reactions (+1 or +2)
           in 70-90% of sensitive subjects.

        -  Frequency of positive, negative, doubtful and irritant reactions for each allergen and
           tested concentration.

        -  Concordance/discordance as compared to the corresponding reference petrolatum allergen.

      Secondary endpoint:

      To evaluate the safety of Disperse blue 106 and Bronopol T.R.U.E. Test allergens in 20 adult
      subjects per allergen with a clinical history of contact dermatitis and a positive patch test
      to the respective reference allergen. Evaluations will include:

        -  The frequency of tape-induced irritation at the test site, incomplete panel adhesion,
           and subject-reported sensations of itching or burning.

        -  The frequency and characterization of adverse events and serious adverse events.

        -  The frequency and characterization of late and/or persistent reactions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic Performance: Optimal Test Allergen Concentration</measure>
    <time_frame>Visits 3-5: 3-21 days after application</time_frame>
    <description>Lowest concentration eliciting 1+ or 2+ positive reactions in 70-90% of subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Positive, Negative, Doubtful and Irritant Reactions for Each Allergen and Concentration</measure>
    <time_frame>Visit 3: 3 days after application</time_frame>
    <description>Percentage (including confidence intervals) of subjects who elicited positive, negative, doubtful and irritant reactions to disperse blue at visit 3- all subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Positive, Negative, Doubtful and Irritant Reactions for Each Allergen and Concentration</measure>
    <time_frame>Visit 4: 7 days after application</time_frame>
    <description>Percent (including confidence intervals) of subjects who elicited positive, negative, doubtful and irritant reactions to disperse blue at visit 4- all subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Positive, Negative, Doubtful and Irritant Reactions for Each Allergen and Concentration</measure>
    <time_frame>Visit 3: 3 days after application</time_frame>
    <description>Percentage (including confidence intervals) of subjects who exhibited positive, negative, doubtful and irritant reactions to bronopol at visit 3- all subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Positive, Negative, Doubtful and Irritant Reactions for Each Allergen and Concentration</measure>
    <time_frame>Visit 4: 7 days after application</time_frame>
    <description>Percentage (including confidence intervals) of subjects who exhibited positive, negative, doubtful and irritant reactions to bronopol at visit 4- all subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concordance Between Investigational Allergen and Reference Allergen</measure>
    <time_frame>Visit 5: 21 days after patch application</time_frame>
    <description>Concordance between disperse blue or bronopol and the respective reference petrolatum allergen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of Irritation (Tape Reactions), Late/Persistent Reactions and Subject-reported Itching or Burning</measure>
    <time_frame>Day 2-21</time_frame>
    <description>Percentage of subjects who exhibited irritation and itching or burning at patch removal (entire panel is evaluated) and late/persistent reactions.
Late reactions occur 7-10 days after patch application Persistent reactions initially occur at 2-4 days after application and persist through 7-21 days after application</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Days 0-21</time_frame>
    <description>The adverse event-reporting period began at application and ended with the Day 21 visit. Adverse events were followed until they resolved. Serious adverse events and those assessed by the investigator as possibly related to the investigational product were to be followed until they resolved or until the investigator assessed them as chronic or stable.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Contact Dermatitis</condition>
  <arm_group>
    <arm_group_label>Sensitives</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with a clinical history and positive patch test (current or previous) to either Disperse Blue 106 or Bronopol. Subjects must otherwise be healthy and fulfill entry criteria.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>T.R.U.E. TEST速 Skin Patch Test: Dose Response Allergens</intervention_name>
    <description>Disperse blue 106 in PVP, 0.15 mg/cm2 Disperse blue 106 in PVP, 0.050 mg/cm2 Disperse blue 106 in PVP, 0.017 mg/cm2 PVP Negative Control Bronopol in PVP, 0.75 mg/cm2 Bronopol in PVP, 0.50 mg/cm2 Bronopol in PVP, 0.25 mg/cm2 Bronopol in PVP, 0.125 mg/cm2
Test patches, with allergens, are placed at day one and removed 48 hours later. The duration of the study lasts 21 days. However, the subject is only exposed to the study allergens for 48 hours.</description>
    <arm_group_label>Sensitives</arm_group_label>
    <other_name>T.R.U.E. TEST速 Skin Patch Test: Panel 3.2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current or previous symptoms and/or history consistent with allergic contact
             dermatitis, and positive patch test (within the past 5 years) to Bronopol OR Current
             or previous symptoms and/or history consistent with allergic contact dermatitis, and a
             positive patch test (within the past 5 years) to Disperse blue 106 or Disperse blue
             106/124 allergen mix.

          -  All subjects must be adults (18 years of age or older) and otherwise in good health.

          -  Premenopausal female subjects must consent to a urine pregnancy test; results must be
             negative for study inclusion.

          -  Informed consent must be signed and understood by each subject, and consistent with
             all institutional, local and national regulations.

        Exclusion Criteria:

          -  Subjects unable to meet inclusion requirements.

          -  Women who are breastfeeding or pregnant.

          -  Topical treatment during the last 7 days with corticosteroids or other
             immunosuppressive agents on or near the test area.

          -  Systemic treatment during the last 7 days with corticosteroids (equivalent to &gt; 10 mg
             prednisone) or other immunosuppressive agents.

          -  Treatment with ultraviolet (UV) light (including tanning) during the previous 3 weeks.

          -  Acute dermatitis outbreak or dermatitis on or near the test area on the back.

          -  Subjects unable to comply with patch test study requirements including multiple return
             visits and activity restrictions (e.g., protecting test panels from excess moisture
             due to showering or vigorous activity).

          -  Subject participation in clinical trials of investigational drugs, treatments or
             devices other than T.R.U.E. Test during this study or 3 weeks prior to inclusion in
             this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evy Paulsen, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Fowler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology Specialists PSC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dermatology Specialists PSC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202-1864</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense C</city>
        <zip>DK-5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2008</study_first_submitted>
  <study_first_submitted_qc>March 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2008</study_first_posted>
  <results_first_submitted>February 21, 2013</results_first_submitted>
  <results_first_submitted_qc>April 6, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 9, 2018</results_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dermatitis, Contact, Bronopol, Disperse Blue 106</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Contact</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronopol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Dates of recruitment: 16 June 2008 through 7 April 2009. This study was conducted at two investigational sites located in Denmark (E Paulsen) and the United States (J Fowler).</recruitment_details>
      <pre_assignment_details>There were no significant events or approaches which caused enrolled participants to be excluded from the trial before assignment to a group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sensitives</title>
          <description>Subjects with a clinical history and positive patch test (current or previous) to either Disperse Blue 106 or Bronopol. Subjects must otherwise be healthy and fulfill entry criteria.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The analysis included all enrolled subjects but it should be noted that subject 5-D220 was not sensitive to either allergen and thus was not included in either population of sensitive subjects; the subject was included in the population of all enrolled subjects.</population>
      <group_list>
        <group group_id="B1">
          <title>Sensitives</title>
          <description>Subjects with a clinical history and positive patch test (current or previous) to either Disperse Blue 106 or Bronopol. Subjects must otherwise be healthy and fulfill entry criteria.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.2" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic Performance: Optimal Test Allergen Concentration</title>
        <description>Lowest concentration eliciting 1+ or 2+ positive reactions in 70-90% of subjects</description>
        <time_frame>Visits 3-5: 3-21 days after application</time_frame>
        <population>Percentage is based on subjects sensitive to each allergen. Results from one subject not included due to no past history of positive patch test.</population>
        <group_list>
          <group group_id="O1">
            <title>Disperse Blue 0.017 mg/cm2</title>
            <description>Percentage of positive test responses</description>
          </group>
          <group group_id="O2">
            <title>Disperse Blue 0.050 mg/cm2</title>
            <description>Percentage of positive test responses</description>
          </group>
          <group group_id="O3">
            <title>Disperse Blue 0.150 mg/cm2</title>
            <description>Percentage of positive test responses</description>
          </group>
          <group group_id="O4">
            <title>Bronopol 0.125 mg/cm2</title>
            <description>Percentage of positive test responses</description>
          </group>
          <group group_id="O5">
            <title>Bronopol 0.250 mg/cm2</title>
            <description>Percentage of positive test responses</description>
          </group>
          <group group_id="O6">
            <title>Bronopol 0.500 mg/cm2</title>
            <description>Percentage of positive test responses</description>
          </group>
          <group group_id="O7">
            <title>Bronopol 0.750 mg/cm2</title>
            <description>Percentage of positive test responses</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic Performance: Optimal Test Allergen Concentration</title>
          <description>Lowest concentration eliciting 1+ or 2+ positive reactions in 70-90% of subjects</description>
          <population>Percentage is based on subjects sensitive to each allergen. Results from one subject not included due to no past history of positive patch test.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="26"/>
                <count group_id="O6" value="26"/>
                <count group_id="O7" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1"/>
                    <measurement group_id="O2" value="47.6"/>
                    <measurement group_id="O3" value="52.4"/>
                    <measurement group_id="O4" value="30.8"/>
                    <measurement group_id="O5" value="23.1"/>
                    <measurement group_id="O6" value="46.2"/>
                    <measurement group_id="O7" value="61.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Positive, Negative, Doubtful and Irritant Reactions for Each Allergen and Concentration</title>
        <description>Percentage (including confidence intervals) of subjects who elicited positive, negative, doubtful and irritant reactions to disperse blue at visit 3- all subjects</description>
        <time_frame>Visit 3: 3 days after application</time_frame>
        <population>All subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Disperse Blue 0.017 mg/cm2 Positive Reactions</title>
            <description>Percentage of subjects who exhibited positive reactions at visit 3</description>
          </group>
          <group group_id="O2">
            <title>Disperse Blue 0.050 mg/cm2 Positive Reactions</title>
            <description>Percentage of subjects who exhibited positive reactions at visit 3</description>
          </group>
          <group group_id="O3">
            <title>Disperse Blue 0.150 mg/cm2 Positive Reactions</title>
            <description>Percentage of subjects who exhibited positive reactions at visit 3</description>
          </group>
          <group group_id="O4">
            <title>Negative Control Positive Reactions</title>
            <description>Percentage of subjects who exhibited positive reactions at visit 3</description>
          </group>
          <group group_id="O5">
            <title>Disperse Blue 0.017 Negative Reactions</title>
            <description>Percentage of subjects who exhibited negative reactions at visit 3</description>
          </group>
          <group group_id="O6">
            <title>Disperse Blue 0.050 mg/cm2 Negative Reactions</title>
            <description>Percentage of subjects who exhibited negative reactions at visit 3</description>
          </group>
          <group group_id="O7">
            <title>Disperse Blue 0.150 mg/cm2 Negative Reactions</title>
            <description>Percentage of subjects who exhibited negative reactions at visit 3</description>
          </group>
          <group group_id="O8">
            <title>Negative Control Negative Reactions</title>
            <description>Percentage of subjects who exhibited negative reactions at visit 3</description>
          </group>
          <group group_id="O9">
            <title>Disperse Blue 0.017 mg/cm2 Irritant Reactions</title>
            <description>Percentage of subjects who exhibited irritant reactions at visit 3</description>
          </group>
          <group group_id="O10">
            <title>Disperse Blue 0.050 mg/cm2 Irritant Reactions</title>
            <description>Percentage of subjects who exhibited irritant reactions at visit 3</description>
          </group>
          <group group_id="O11">
            <title>Disperse Blue 0.150 mg/cm2 Irritant Reactions</title>
            <description>Percentage of subjects who exhibited irritant reactions at visit 3</description>
          </group>
          <group group_id="O12">
            <title>Negative Control Irritant Reactions</title>
            <description>Percentage of subjects who exhibited irritant reactions at visit 3</description>
          </group>
          <group group_id="O13">
            <title>Disperse Blue 0.017 mg/cm2 Doubtful Reactions</title>
            <description>Percentage of subjects who exhibited doubtful reactions at visit 3</description>
          </group>
          <group group_id="O14">
            <title>Disperse Blue 0.050 mg/cm2 Doubtful Reactions</title>
            <description>Percentage of subjects who exhibited doubtful reactions at visit 3</description>
          </group>
          <group group_id="O15">
            <title>Disperse Blue 0.150 mg/cm2 Doubtful Reactions</title>
            <description>Percentage of subjects who exhibited doubtful reactions at visit 3</description>
          </group>
          <group group_id="O16">
            <title>Negative Control Doubtful Reactions</title>
            <description>Percentage of subjects who exhibited doubtful reactions at visit 3</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Positive, Negative, Doubtful and Irritant Reactions for Each Allergen and Concentration</title>
          <description>Percentage (including confidence intervals) of subjects who elicited positive, negative, doubtful and irritant reactions to disperse blue at visit 3- all subjects</description>
          <population>All subjects</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="48"/>
                <count group_id="O7" value="48"/>
                <count group_id="O8" value="48"/>
                <count group_id="O9" value="48"/>
                <count group_id="O10" value="48"/>
                <count group_id="O11" value="48"/>
                <count group_id="O12" value="48"/>
                <count group_id="O13" value="48"/>
                <count group_id="O14" value="48"/>
                <count group_id="O15" value="48"/>
                <count group_id="O16" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" lower_limit="7.5" upper_limit="30.2"/>
                    <measurement group_id="O2" value="18.8" lower_limit="8.9" upper_limit="32.6"/>
                    <measurement group_id="O3" value="25.0" lower_limit="13.6" upper_limit="39.6"/>
                    <measurement group_id="O4" value="2.1" lower_limit="0.1" upper_limit="11.1"/>
                    <measurement group_id="O5" value="75.0" lower_limit="60.4" upper_limit="86.4"/>
                    <measurement group_id="O6" value="77.1" lower_limit="62.7" upper_limit="88.0"/>
                    <measurement group_id="O7" value="72.9" lower_limit="58.2" upper_limit="84.7"/>
                    <measurement group_id="O8" value="91.7" lower_limit="80.0" upper_limit="97.7"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="7.4"/>
                    <measurement group_id="O10" value="0.0" lower_limit="0.0" upper_limit="7.4"/>
                    <measurement group_id="O11" value="0.0" lower_limit="0.0" upper_limit="7.4"/>
                    <measurement group_id="O12" value="0.0" lower_limit="0.0" upper_limit="7.4"/>
                    <measurement group_id="O13" value="8.3" lower_limit="2.3" upper_limit="20.0"/>
                    <measurement group_id="O14" value="4.2" lower_limit="0.5" upper_limit="14.3"/>
                    <measurement group_id="O15" value="2.1" lower_limit="0.1" upper_limit="11.1"/>
                    <measurement group_id="O16" value="6.3" lower_limit="1.3" upper_limit="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Positive, Negative, Doubtful and Irritant Reactions for Each Allergen and Concentration</title>
        <description>Percent (including confidence intervals) of subjects who elicited positive, negative, doubtful and irritant reactions to disperse blue at visit 4- all subjects</description>
        <time_frame>Visit 4: 7 days after application</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Disperse Blue 0.017 mg/cm2 Positive Reactions</title>
            <description>Percentage of subjects who exhibited positive reactions at visit 4</description>
          </group>
          <group group_id="O2">
            <title>Disperse Blue 0.050 mg/cm2 Positive Reactions</title>
            <description>Percentage of subjects who exhibited positive reactions at visit 4</description>
          </group>
          <group group_id="O3">
            <title>Disperse Blue 0.150 mg/cm2 Positive Reactions</title>
            <description>Percentage of subjects who exhibited positive reactions at visit 4</description>
          </group>
          <group group_id="O4">
            <title>Negative Control Positive Reactions</title>
            <description>Percentage of subjects who exhibited positive reactions at visit 4</description>
          </group>
          <group group_id="O5">
            <title>Disperse Blue 0.017 Negative Reactions</title>
            <description>Percentage of subjects who exhibited negative reactions at visit 4</description>
          </group>
          <group group_id="O6">
            <title>Disperse Blue 0.050 mg/cm2 Negative Reactions</title>
            <description>Percentage of subjects who exhibited negative reactions at visit 4</description>
          </group>
          <group group_id="O7">
            <title>Disperse Blue 0.150 mg/cm2 Negative Reactions</title>
            <description>Percentage of subjects who exhibited negative reactions at visit 4</description>
          </group>
          <group group_id="O8">
            <title>Negative Control Negative Reactions</title>
            <description>Percentage of subjects who exhibited negative reactions at visit 4</description>
          </group>
          <group group_id="O9">
            <title>Disperse Blue 0.017 mg/cm2 Irritant Reactions</title>
            <description>Percentage of subjects who exhibited irritant reactions at visit 4</description>
          </group>
          <group group_id="O10">
            <title>Disperse Blue 0.050 mg/cm2 Irritant Reactions</title>
            <description>Percentage of subjects who exhibited irritant reactions at visit 4</description>
          </group>
          <group group_id="O11">
            <title>Disperse Blue 0.150 mg/cm2 Irritant Reactions</title>
            <description>Percentage of subjects who exhibited irritant reactions at visit 4</description>
          </group>
          <group group_id="O12">
            <title>Negative Control Irritant Reactions</title>
            <description>Percentage of subjects who exhibited irritant reactions at visit 4</description>
          </group>
          <group group_id="O13">
            <title>Disperse Blue 0.017 mg/cm2 Doubtful Reactions</title>
            <description>Percentage of subjects who exhibited doubtful reactions at visit 4</description>
          </group>
          <group group_id="O14">
            <title>Disperse Blue 0.050 mg/cm2 Doubtful Reactions</title>
            <description>Percentage of subjects who exhibited doubtful reactions at visit 4</description>
          </group>
          <group group_id="O15">
            <title>Disperse Blue 0.150 mg/cm2 Doubtful Reactions</title>
            <description>Percentage of subjects who exhibited doubtful reactions at visit 4</description>
          </group>
          <group group_id="O16">
            <title>Negative Control Doubtful Reactions</title>
            <description>Percentage of subjects who exhibited doubtful reactions at visit 4</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Positive, Negative, Doubtful and Irritant Reactions for Each Allergen and Concentration</title>
          <description>Percent (including confidence intervals) of subjects who elicited positive, negative, doubtful and irritant reactions to disperse blue at visit 4- all subjects</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="48"/>
                <count group_id="O7" value="48"/>
                <count group_id="O8" value="48"/>
                <count group_id="O9" value="48"/>
                <count group_id="O10" value="48"/>
                <count group_id="O11" value="48"/>
                <count group_id="O12" value="48"/>
                <count group_id="O13" value="48"/>
                <count group_id="O14" value="48"/>
                <count group_id="O15" value="48"/>
                <count group_id="O16" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8" lower_limit="8.9" upper_limit="32.6"/>
                    <measurement group_id="O2" value="18.8" lower_limit="8.9" upper_limit="32.6"/>
                    <measurement group_id="O3" value="27.1" lower_limit="15.3" upper_limit="41.8"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.4"/>
                    <measurement group_id="O5" value="75.0" lower_limit="60.4" upper_limit="86.4"/>
                    <measurement group_id="O6" value="72.9" lower_limit="58.2" upper_limit="84.7"/>
                    <measurement group_id="O7" value="70.8" lower_limit="55.9" upper_limit="83.0"/>
                    <measurement group_id="O8" value="97.9" lower_limit="88.9" upper_limit="99.9"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="7.4"/>
                    <measurement group_id="O10" value="0.0" lower_limit="0.0" upper_limit="7.4"/>
                    <measurement group_id="O11" value="0.0" lower_limit="0.0" upper_limit="7.4"/>
                    <measurement group_id="O12" value="0.0" lower_limit="0.0" upper_limit="7.4"/>
                    <measurement group_id="O13" value="6.3" lower_limit="1.3" upper_limit="17.2"/>
                    <measurement group_id="O14" value="8.3" lower_limit="2.3" upper_limit="20.0"/>
                    <measurement group_id="O15" value="2.1" lower_limit="0.1" upper_limit="11.1"/>
                    <measurement group_id="O16" value="2.1" lower_limit="0.1" upper_limit="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Positive, Negative, Doubtful and Irritant Reactions for Each Allergen and Concentration</title>
        <description>Percentage (including confidence intervals) of subjects who exhibited positive, negative, doubtful and irritant reactions to bronopol at visit 3- all subjects</description>
        <time_frame>Visit 3: 3 days after application</time_frame>
        <population>Data from one subject not included because subject did not have a past positive response to either allergen.</population>
        <group_list>
          <group group_id="O1">
            <title>Bronopol 0.1 mg/cm2 Positive Reactions</title>
            <description>Percentage of subjects who exhibited positive reactions at visit 3</description>
          </group>
          <group group_id="O2">
            <title>Bronopol 0.250 mg/cm2 Positive Reactions</title>
            <description>Percentage of subjects who exhibited positive reactions at visit 3</description>
          </group>
          <group group_id="O3">
            <title>Bronopol 0.500 mg/cm2 Positive Reactions</title>
            <description>Percentage of subjects who exhibited positive reactions at visit 3</description>
          </group>
          <group group_id="O4">
            <title>Bronopol 0.750 mg/cm2 Positive Reactions</title>
            <description>Percentage of subjects who exhibited positive reactions at visit 3</description>
          </group>
          <group group_id="O5">
            <title>Bronopol 0.1 Negative Reactions</title>
            <description>Percentage of subjects who exhibited negative reactions at visit 3</description>
          </group>
          <group group_id="O6">
            <title>Bronopol 0.250 mg/cm2 Negative Reactions</title>
            <description>Percentage of subjects who exhibited negative reactions at visit 3</description>
          </group>
          <group group_id="O7">
            <title>Bronopol 0.500 mg/cm2 Negative Reactions</title>
            <description>Percentage of subjects who exhibited negative reactions at visit 3</description>
          </group>
          <group group_id="O8">
            <title>Bronopol 0.750 mg/cm2 Negative Reactions</title>
            <description>Percentage of subjects who exhibited negative reactions at visit 3</description>
          </group>
          <group group_id="O9">
            <title>Bronopol 0.1 mg/cm2 Irritant Reactions</title>
            <description>Percentage of subjects who exhibited irritant reactions at visit 3</description>
          </group>
          <group group_id="O10">
            <title>Bronopol 0.250 mg/cm2 Irritant Reactions</title>
            <description>Percentage of subjects who exhibited irritant reactions at visit 3</description>
          </group>
          <group group_id="O11">
            <title>Bronopol 0.500 mg/cm2 Irritant Reactions</title>
            <description>Percentage of subjects who exhibited irritant reactions at visit 3</description>
          </group>
          <group group_id="O12">
            <title>Bronopol 0.750 mg/cm2 Irritant Reactions</title>
            <description>Percentage of subjects who exhibited irritant reactions at visit 3</description>
          </group>
          <group group_id="O13">
            <title>Bronopol 0.1 mg/cm2 Doubtful Reactions</title>
            <description>Percentage of subjects who exhibited doubtful reactions at visit 3</description>
          </group>
          <group group_id="O14">
            <title>Bronopol 0.250 mg/cm2 Doubtful Reactions</title>
            <description>Percentage of subjects who exhibited doubtful reactions at visit 3</description>
          </group>
          <group group_id="O15">
            <title>Bronopol 0.500 mg/cm2 Doubtful Reactions</title>
            <description>Percentage of subjects who exhibited doubtful reactions at visit 3</description>
          </group>
          <group group_id="O16">
            <title>Bronopol 0.750 mg/cm2 Doubtful Reactions</title>
            <description>Percentage of subjects who exhibited doubtful reactions at visit 3</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Positive, Negative, Doubtful and Irritant Reactions for Each Allergen and Concentration</title>
          <description>Percentage (including confidence intervals) of subjects who exhibited positive, negative, doubtful and irritant reactions to bronopol at visit 3- all subjects</description>
          <population>Data from one subject not included because subject did not have a past positive response to either allergen.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="47"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="47"/>
                <count group_id="O9" value="47"/>
                <count group_id="O10" value="47"/>
                <count group_id="O11" value="47"/>
                <count group_id="O12" value="47"/>
                <count group_id="O13" value="47"/>
                <count group_id="O14" value="47"/>
                <count group_id="O15" value="47"/>
                <count group_id="O16" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" lower_limit="6.1" upper_limit="27.8"/>
                    <measurement group_id="O2" value="14.6" lower_limit="6.1" upper_limit="27.8"/>
                    <measurement group_id="O3" value="25.0" lower_limit="13.6" upper_limit="39.6"/>
                    <measurement group_id="O4" value="45.8" lower_limit="31.4" upper_limit="60.8"/>
                    <measurement group_id="O5" value="79.2" lower_limit="65.0" upper_limit="89.5"/>
                    <measurement group_id="O6" value="72.9" lower_limit="58.2" upper_limit="84.7"/>
                    <measurement group_id="O7" value="58.3" lower_limit="43.2" upper_limit="72.4"/>
                    <measurement group_id="O8" value="37.5" lower_limit="24.0" upper_limit="52.6"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="7.4"/>
                    <measurement group_id="O10" value="0.0" lower_limit="0.0" upper_limit="7.4"/>
                    <measurement group_id="O11" value="2.1" lower_limit="0.1" upper_limit="11.1"/>
                    <measurement group_id="O12" value="0.0" lower_limit="0.0" upper_limit="7.4"/>
                    <measurement group_id="O13" value="6.3" lower_limit="1.3" upper_limit="17.2"/>
                    <measurement group_id="O14" value="12.5" lower_limit="4.7" upper_limit="25.2"/>
                    <measurement group_id="O15" value="14.6" lower_limit="6.1" upper_limit="27.8"/>
                    <measurement group_id="O16" value="16.7" lower_limit="7.5" upper_limit="30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Positive, Negative, Doubtful and Irritant Reactions for Each Allergen and Concentration</title>
        <description>Percentage (including confidence intervals) of subjects who exhibited positive, negative, doubtful and irritant reactions to bronopol at visit 4- all subjects</description>
        <time_frame>Visit 4: 7 days after application</time_frame>
        <population>Data from one subject not included because subject did not have past positive response to either allergen.</population>
        <group_list>
          <group group_id="O1">
            <title>Bronopol 0.125 mg/cm2 Positive Reactions</title>
            <description>Percentage of subjects who exhibited positive reactions at visit 4</description>
          </group>
          <group group_id="O2">
            <title>Bronopol 0.250 mg/cm2 Positive Reactions</title>
            <description>Percentage of subjects who exhibited positive reactions at visit 4</description>
          </group>
          <group group_id="O3">
            <title>Bronopol 0.500 mg/cm2 Positive Reactions</title>
            <description>Percentage of subjects who exhibited positive reactions at visit 4</description>
          </group>
          <group group_id="O4">
            <title>Bronopol 0.750 mg/cm2 Positive Reactions</title>
            <description>Percentage of subjects who exhibited positive reactions at visit 4</description>
          </group>
          <group group_id="O5">
            <title>Bronopol 0.125 Negative Reactions</title>
            <description>Percentage of subjects who exhibited negative reactions at visit 4</description>
          </group>
          <group group_id="O6">
            <title>Bronopol 0.250 mg/cm2 Negative Reactions</title>
            <description>Percentage of subjects who exhibited negative reactions at visit 4</description>
          </group>
          <group group_id="O7">
            <title>Bronopol 0.500 mg/cm2 Negative Reactions</title>
            <description>Percentage of subjects who exhibited negative reactions at visit 4</description>
          </group>
          <group group_id="O8">
            <title>Bronopol 0.750 mg/cm2 Negative Reactions</title>
            <description>Percentage of subjects who exhibited negative reactions at visit 4</description>
          </group>
          <group group_id="O9">
            <title>Bronopol 0.125 mg/cm2 Irritant Reactions</title>
            <description>Percentage of subjects who exhibited irritant reactions at visit 4</description>
          </group>
          <group group_id="O10">
            <title>Bronopol 0.250 mg/cm2 Irritant Reactions</title>
            <description>Percentage of subjects who exhibited irritant reactions at visit 4</description>
          </group>
          <group group_id="O11">
            <title>Bronopol 0.500 mg/cm2 Irritant Reactions</title>
            <description>Percentage of subjects who exhibited irritant reactions at visit 4</description>
          </group>
          <group group_id="O12">
            <title>Bronopol 0.750 mg/cm2 Irritant Reactions</title>
            <description>Percentage of subjects who exhibited irritant reactions at visit 4</description>
          </group>
          <group group_id="O13">
            <title>Bronopol 0.125 mg/cm2 Doubtful Reactions</title>
            <description>Percentage of subjects who exhibited doubtful reactions at visit 4</description>
          </group>
          <group group_id="O14">
            <title>Bronopol 0.250 mg/cm2 Doubtful Reactions</title>
            <description>Percentage of subjects who exhibited doubtful reactions at visit 4</description>
          </group>
          <group group_id="O15">
            <title>Bronopol 0.500 mg/cm2 Doubtful Reactions</title>
            <description>Percentage of subjects who exhibited doubtful reactions at visit 4</description>
          </group>
          <group group_id="O16">
            <title>Bronopol 0.750 mg/cm2 Doubtful Reactions</title>
            <description>Percentage of subjects who exhibited doubtful reactions at visit 4</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Positive, Negative, Doubtful and Irritant Reactions for Each Allergen and Concentration</title>
          <description>Percentage (including confidence intervals) of subjects who exhibited positive, negative, doubtful and irritant reactions to bronopol at visit 4- all subjects</description>
          <population>Data from one subject not included because subject did not have past positive response to either allergen.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="47"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="47"/>
                <count group_id="O9" value="47"/>
                <count group_id="O10" value="47"/>
                <count group_id="O11" value="47"/>
                <count group_id="O12" value="47"/>
                <count group_id="O13" value="47"/>
                <count group_id="O14" value="47"/>
                <count group_id="O15" value="47"/>
                <count group_id="O16" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" lower_limit="6.2" upper_limit="28.3"/>
                    <measurement group_id="O2" value="17.0" lower_limit="7.6" upper_limit="30.8"/>
                    <measurement group_id="O3" value="21.3" lower_limit="10.7" upper_limit="35.7"/>
                    <measurement group_id="O4" value="29.8" lower_limit="17.3" upper_limit="44.9"/>
                    <measurement group_id="O5" value="78.7" lower_limit="64.3" upper_limit="89.3"/>
                    <measurement group_id="O6" value="74.5" lower_limit="59.7" upper_limit="86.1"/>
                    <measurement group_id="O7" value="59.6" lower_limit="44.3" upper_limit="73.6"/>
                    <measurement group_id="O8" value="57.4" lower_limit="42.2" upper_limit="71.7"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="7.5"/>
                    <measurement group_id="O10" value="0.0" lower_limit="0.0" upper_limit="7.5"/>
                    <measurement group_id="O11" value="4.3" lower_limit="0.5" upper_limit="14.5"/>
                    <measurement group_id="O12" value="8.5" lower_limit="2.4" upper_limit="20.4"/>
                    <measurement group_id="O13" value="6.4" lower_limit="1.3" upper_limit="17.5"/>
                    <measurement group_id="O14" value="8.5" lower_limit="2.4" upper_limit="20.4"/>
                    <measurement group_id="O15" value="14.9" lower_limit="6.2" upper_limit="28.3"/>
                    <measurement group_id="O16" value="4.3" lower_limit="0.5" upper_limit="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concordance Between Investigational Allergen and Reference Allergen</title>
        <description>Concordance between disperse blue or bronopol and the respective reference petrolatum allergen</description>
        <time_frame>Visit 5: 21 days after patch application</time_frame>
        <population>Data from one subject not included because subject did not have past positive response to either allergen.</population>
        <group_list>
          <group group_id="O1">
            <title>Disperse Blue 0.017 mg/cm2</title>
            <description>Concordance between disperse blue and the reference petrolatum allergen</description>
          </group>
          <group group_id="O2">
            <title>Disperse Blue 0.050 mg/cm2</title>
            <description>Concordance between disperse blue and the reference petrolatum allergen</description>
          </group>
          <group group_id="O3">
            <title>Disperse Blue 0.150 mg/cm2</title>
            <description>Concordance between disperse blue and the reference petrolatum allergen</description>
          </group>
          <group group_id="O4">
            <title>Bronopol 0.125 mg/cm2</title>
            <description>Concordance between bronopol and the reference petrolatum allergen</description>
          </group>
          <group group_id="O5">
            <title>Bronopol 0.250 mg/cm2</title>
            <description>Concordance between bronopol and the reference petrolatum allergen</description>
          </group>
          <group group_id="O6">
            <title>Bronopol 0.500 mg/cm2</title>
            <description>Concordance between bronopol and the reference petrolatum allergen</description>
          </group>
          <group group_id="O7">
            <title>Bronopol 0.750 mg/cm2</title>
            <description>Concordance between bronopol and the reference petrolatum allergen</description>
          </group>
        </group_list>
        <measure>
          <title>Concordance Between Investigational Allergen and Reference Allergen</title>
          <description>Concordance between disperse blue or bronopol and the respective reference petrolatum allergen</description>
          <population>Data from one subject not included because subject did not have past positive response to either allergen.</population>
          <units>percentage of agreement</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="26"/>
                <count group_id="O6" value="26"/>
                <count group_id="O7" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.0" lower_limit="58.1" upper_limit="94.6"/>
                    <measurement group_id="O2" value="95.2" lower_limit="76.2" upper_limit="99.9"/>
                    <measurement group_id="O3" value="90.5" lower_limit="69.6" upper_limit="98.8"/>
                    <measurement group_id="O4" value="84.6" lower_limit="65.1" upper_limit="95.6"/>
                    <measurement group_id="O5" value="100.0" lower_limit="86.8" upper_limit="100.0"/>
                    <measurement group_id="O6" value="76.9" lower_limit="56.4" upper_limit="91.0"/>
                    <measurement group_id="O7" value="61.5" lower_limit="40.6" upper_limit="79.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Irritation (Tape Reactions), Late/Persistent Reactions and Subject-reported Itching or Burning</title>
        <description>Percentage of subjects who exhibited irritation and itching or burning at patch removal (entire panel is evaluated) and late/persistent reactions.
Late reactions occur 7-10 days after patch application Persistent reactions initially occur at 2-4 days after application and persist through 7-21 days after application</description>
        <time_frame>Day 2-21</time_frame>
        <population>Data from one subject not included because subject did not have past positive response to either allergen.</population>
        <group_list>
          <group group_id="O1">
            <title>Disperse Blue Irritation Reactions</title>
            <description>Percentage of subjects who exhibited irritation (tape reactions) to disperse blue panel</description>
          </group>
          <group group_id="O2">
            <title>Bronopol Irritation Reactions</title>
            <description>Percentage of subjects who exhibited irritation (tape reactions) to bronopol panel</description>
          </group>
          <group group_id="O3">
            <title>Disperse Blue Itching and/or Burning</title>
            <description>Percentage of subjects who exhibited itching and/or burning to disperse blue panel</description>
          </group>
          <group group_id="O4">
            <title>Bronopol Itching and/or Burning</title>
            <description>Percentage of subjects who exhibited itching and/or burning to bronopol panel</description>
          </group>
          <group group_id="O5">
            <title>Disperse Blue 0.017 Late Reactions</title>
            <description>Percentage of subjects who exhibited late reactions</description>
          </group>
          <group group_id="O6">
            <title>Disperse Blue 0.050 mg/cm2 Late Reactions</title>
            <description>Percentage of subjects who exhibited late reactions</description>
          </group>
          <group group_id="O7">
            <title>Disperse Blue 0.150 mg/cm2 Late Reactions</title>
            <description>Percentage of subjects who exhibited late reactions</description>
          </group>
          <group group_id="O8">
            <title>Negative Control Late Reactions</title>
            <description>Percentage of subjects who exhibited late reactions</description>
          </group>
          <group group_id="O9">
            <title>Disperse Blue 0.017 mg/cm2 Persistent Reactions</title>
            <description>Percentage of subjects who exhibited persistent reactions</description>
          </group>
          <group group_id="O10">
            <title>Disperse Blue 0.050 mg/cm2 Persistent Reactions</title>
            <description>Percentage of subjects who exhibited persistent reactions</description>
          </group>
          <group group_id="O11">
            <title>Disperse Blue 0.150 mg/cm2 Persistent Reactions</title>
            <description>Percentage of subjects who exhibited persistent reactions</description>
          </group>
          <group group_id="O12">
            <title>Negative Control Persistent Reactions</title>
            <description>Percentage of subjects who exhibited persistent reactions</description>
          </group>
          <group group_id="O13">
            <title>Bronopol 0.125 mg/cm2 Late Reactions</title>
            <description>Percentage of subjects who exhibited late reactions</description>
          </group>
          <group group_id="O14">
            <title>Bronopol 0.250 mg/cm2 Late Reactions</title>
            <description>Percentage of subjects who exhibited late reactions</description>
          </group>
          <group group_id="O15">
            <title>Bronopol 0.500 mg/cm2 Late Reactions</title>
            <description>Percentage of subjects who exhibited late reactions</description>
          </group>
          <group group_id="O16">
            <title>Bronopol 0.750 mg/cm2 LateReactions</title>
            <description>Percentage of subjects who exhibited late reactions</description>
          </group>
          <group group_id="O17">
            <title>Bronopol 0.125 mg/cm2 Persistent Reactions</title>
            <description>Percentage of subjects who exhibited persistent reactions</description>
          </group>
          <group group_id="O18">
            <title>Bronopol 0.250 mg/cm2 Persistent Reactions</title>
            <description>Percentage of subjects who exhibited persistent reactions</description>
          </group>
          <group group_id="O19">
            <title>Bronopol 0.500 mg/cm2 Persistent Reactions</title>
            <description>Percentage of subjects who exhibited persistent reactions</description>
          </group>
          <group group_id="O20">
            <title>Bronopol 0.750 mg/cm2 Persistent Reactions</title>
            <description>Percentage of subjects who exhibited persistent reactions</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Irritation (Tape Reactions), Late/Persistent Reactions and Subject-reported Itching or Burning</title>
          <description>Percentage of subjects who exhibited irritation and itching or burning at patch removal (entire panel is evaluated) and late/persistent reactions.
Late reactions occur 7-10 days after patch application Persistent reactions initially occur at 2-4 days after application and persist through 7-21 days after application</description>
          <population>Data from one subject not included because subject did not have past positive response to either allergen.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="21"/>
                <count group_id="O7" value="21"/>
                <count group_id="O8" value="21"/>
                <count group_id="O9" value="21"/>
                <count group_id="O10" value="21"/>
                <count group_id="O11" value="21"/>
                <count group_id="O12" value="21"/>
                <count group_id="O13" value="26"/>
                <count group_id="O14" value="26"/>
                <count group_id="O15" value="26"/>
                <count group_id="O16" value="26"/>
                <count group_id="O17" value="26"/>
                <count group_id="O18" value="26"/>
                <count group_id="O19" value="26"/>
                <count group_id="O20" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4"/>
                    <measurement group_id="O2" value="65.4"/>
                    <measurement group_id="O3" value="76.2"/>
                    <measurement group_id="O4" value="73.1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="19.0"/>
                    <measurement group_id="O10" value="19.0"/>
                    <measurement group_id="O11" value="28.6"/>
                    <measurement group_id="O12" value="1.9"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="11.5"/>
                    <measurement group_id="O18" value="15.4"/>
                    <measurement group_id="O19" value="11.5"/>
                    <measurement group_id="O20" value="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>The adverse event-reporting period began at application and ended with the Day 21 visit. Adverse events were followed until they resolved. Serious adverse events and those assessed by the investigator as possibly related to the investigational product were to be followed until they resolved or until the investigator assessed them as chronic or stable.</description>
        <time_frame>Days 0-21</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adverse Events Related to Investigational Panel</title>
            <description>Number of reported adverse events related to investigational or reference allergens.</description>
          </group>
          <group group_id="O2">
            <title>Adverse Events Not Related</title>
            <description>Number of adverse events not related to investigational or reference allergens</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>The adverse event-reporting period began at application and ended with the Day 21 visit. Adverse events were followed until they resolved. Serious adverse events and those assessed by the investigator as possibly related to the investigational product were to be followed until they resolved or until the investigator assessed them as chronic or stable.</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 through Day 21</time_frame>
      <desc>Serious or possibly related events were to be followed until they resolved or assessed as chronic or stable</desc>
      <group_list>
        <group group_id="E1">
          <title>All Subjects</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upset stomach</sub_title>
                <description>Event was not related to the investigational panel.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <description>Event could not be attributed to a single allergen or allergen concentration. It was determined to be related to the the entire panel.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There were no limitations or caveats which led to unreadable or uninterpretable data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Evy Paulsen, MD</name_or_title>
      <organization>Institute of Clinical Research, Department of Dermoto Venerology and Allergy Center</organization>
      <phone>+45 65 41 27 08</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

